Test Code LAB5330 Lyme Disease, Molecular Detection, PCR, Varies
Ordering Guidance
This assay does not detect Borrelia miyamotoi. If infection with this organism is suspected, order BMIPB / Borrelia miyamotoi Detection, PCR, Blood or BMIYC / Borrelia miyamotoi Detection, PCR, Spinal Fluid.
Necessary Information
Specimen source is required.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Spinal fluid
Container/Tube: Sterile vial
Specimen Volume: 1 mL
Collection Instructions: Label specimen as spinal fluid.
Specimen Type: Synovial fluid
Container/Tube: Sterile vial
Specimen Volume: 1 mL
Collection Instructions: Label specimen as synovial fluid.
Specimen Type: Tissue (fresh only)
Sources: Skin or synovial biopsy
Container/Tube: Sterile container with normal saline
Specimen Volume: Approximately 4 mm(3)
Collection Instructions:
1. Submit only fresh tissue.
2. Skin biopsies:
a. Wash biopsy site with an antiseptic soap. Thoroughly rinse area with sterile water. Do not use alcohol or iodine preparations. A local anesthetic may be used.
b. Biopsy specimens are best taken by punch biopsy to include full thickness of dermis.
3. Label specimen with source of tissue.
Useful For
Supporting the diagnosis of Lyme disease in conjunction with serologic testing
Specific indications including testing skin biopsies when a rash lesion is not characteristic of erythema migrans and testing synovial fluid or synovium to support the diagnosis of Lyme arthritis
This test should not be used to screen asymptomatic patients.
Testing Algorithm
The following algorithms are available:
Special Instructions
Reporting Name
Lyme Disease, PCR, VariesSpecimen Type
VariesSpecimen Minimum Volume
Spinal fluid: 0.3 mL; Synovial fluid: 0.5 mL; Tissue: See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Varies | Refrigerated (preferred) | 7 days |
| Frozen | 7 days |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
Negative
Reference values apply to all ages.
Supportive Data
The following validation data supports the use of this assay for clinical testing.
Analytical Sensitivity/Limit of Detection:
The lower limit of detection (LOD) is approximately 300 to 1000 genomic copies/mL in cerebrospinal fluid (CSF), tissue, blood, and synovial fluid.
Accuracy/Diagnostic Sensitivity and Specificity:
Spiking studies of whole organism in fresh tissue, synovial fluid, and CSF (spiked near the approximate LOD) showed 100% recovery.
Analytical Specificity:
No polymerase chain reaction signal was obtained from the extracts of 22 bacterial, viral, parasitic, and fungal isolates that can cause symptoms similar to Lyme disease, including Rickettsia rickettsii, Rickettsia typhi, Ehrlichia canis, Babesia microti, Plasmodium falciparum, Plasmodium vivax, Bartonella henselae, Bartonella quintana, herpes simplex virus, and Toxoplasma gondii. Relapsing fever borreliae (including Borrelia miyamotoi) are also not detected with this assay.
Precision:
Interassay precision was 100%, and intra-assay precision was 100%.
Reference Range:
The reference range for this assay is negative. This assay is only to be used for patients with a clinical history and symptoms consistent with Lyme disease and must be interpreted in the context of serologic tests, which are the gold standard for diagnosis of Lyme disease.
Reportable Range:
This is a qualitative assay, and the results are reported as negative or positive for targeted Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, or Borrelia mayonii.
Method Description
Nucleic acid is extracted from clinical specimens using the automated MagNA Pure LC instrument system. The extract is then transferred to individual wells of a 96-well plate for amplification. The LightCycler is an automated instrument that amplifies and monitors the development of target nucleic acid (amplicon) after each cycle of polymerase chain reaction (PCR). The DNA target for PCR assay is the 283-base pairs plasminogen-binding protein gene (OppA2), which is present at a frequency of 1 copy per organism in all 4 confirmed pathogenic species of the Borrelia burgdorferi sensu lato genogroup (B burgdorferi sensu stricto, Borrelia afzelii, Borrelia garinii, and Borrelia mayonii). A specific base pair DNA target sequence is amplified by PCR. The detection of amplicon is based on fluorescence resonance energy transfer, which utilizes 1 hybridization probe with a donor fluorophore, fluorescein, at the 3' end, and a second hybridization probe with an acceptor fluorophore, LC-Red 610, at the 5' end. When the target amplicon is present, the LC-Red 610 emits a measurable and quantifiable light signal at a specific wavelength. Presence of the specific organism nucleic acid may be confirmed by performing a melting curve analysis of the amplicon. Using features of the melting curve analysis, the assay primers and specific hybridization probes are able to detect and differentiate B burgdorferi sensu stricto from B mayonii, B afzelii, and B garinii, although the melting curve analysis cannot differentiate between B afzelii and B garinii. Each assay run can be completed within 60 minutes.(Unpublished Mayo method)
Day(s) Performed
Monday through Sunday
Report Available
Same day/1 to 4 daysSpecimen Retention Time
1 weekPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
87476
87798 x 2
87801 (if appropriate for government payers)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| LYMPV | Lyme Disease, PCR, Varies | 94253-2 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| LYMS | Specimen Source | 31208-2 |
| 618333 | B. burgdorferi PCR | 94250-8 |
| 618334 | B. mayonii PCR | 94251-6 |
| 618335 | B. garinii/B. afzelii PCR | 94252-4 |
| 618336 | Lyme CSF Comment | 59464-8 |
Forms
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.